ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Current capacity 1000 tests per day

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Oct 02, 2021 11:16am

156 Views

Post# 33957447

RE:RE:RE:RE:RE:RE:RE:Current capacity 1000 tests per day

Not seeing the actual legal JV agreement, one way that would make any sense in the revenue sharing JV carried out under the private company name "Immusafe Labe Inc." is that after all expenses, dividends will be paid out to the 2 partners (the shareholders) in the JV, Promis and BCNI equally, from retained earnings of "Immusafe Labs Inc".

jmo
G1945V

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks